CCCC (STOCKS)
C4 Therapeutics, Inc.
$4.140000
+0.220000 (+5.61%)
Prev close: $3.920000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Andrew J. Hirsch
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $457.20M
- Employees
- 110
- P/E (TTM)
- -3.50
- P/B (TTM)
- 1.74
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $34.86M |
| Benefits Costs and Expenses | $138.54M |
| Costs And Expenses | $138.54M |
| Nonoperating Income/Loss | $10.16M |
| Operating Expenses | $148.70M |
| Research and Development | $101.77M |
| Other Operating Expenses | $44.97M |
| Operating Income/Loss | -$113.84M |
| Income/Loss From Continuing Operations After Tax | -$103.80M |
| Income/Loss From Continuing Operations Before Tax | -$103.68M |
| Income Tax Expense/Benefit | $121.00K |
| Net Income/Loss | -$103.80M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$103.80M |
| Net Income/Loss Available To Common Stockholders, Basic | -$103.80M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.10 |
| Diluted Earnings Per Share | -$1.10 |
| Basic Average Shares | 281,064,364 |
| Diluted Average Shares | 281,064,364 |
| Assets | $328.86M |
| Current Assets | $245.37M |
| Cash | $268.30M |
| Accounts Receivable | $2.88M |
| Noncurrent Assets | $83.49M |
| Fixed Assets | $4.49M |
| Other Non-current Assets | $79.00M |
| Liabilities | $94.61M |
| Current Liabilities | $27.25M |
| Accounts Payable | $773.00K |
| Other Current Liabilities | $26.48M |
| Noncurrent Liabilities | $67.37M |
| Equity | $234.25M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $234.25M |
| Liabilities And Equity | $328.86M |
| Net Cash Flow From Operating Activities | -$95.35M |
| Net Cash Flow From Operating Activities, Continuing | -$95.35M |
| Net Cash Flow From Investing Activities | -$21.57M |
| Net Cash Flow From Investing Activities, Continuing | -$21.57M |
| Net Cash Flow From Financing Activities | $126.91M |
| Net Cash Flow From Financing Activities, Continuing | $126.91M |
| Net Cash Flow | $9.98M |
| Net Cash Flow, Continuing | $9.98M |
| Comprehensive Income/Loss | -$104.15M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$104.22M |
| Other Comprehensive Income/Loss | -$137.51M |